Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announced an investigation into Emergent BioSolutions regarding potential federal securities law violations. The investigation follows the company's August 5 disclosure of a $191.3 million impairment charge on NARCAN and a 10.8% cut to full-year revenue guidance.
Key figures
- Gaap net loss
- $180.2 million
- Impairment charge
- $191.3 million
- Guidance cut midpoint
- 10.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.